KRAS and colorectal cancer: In a randomized phase III trial, patients with refractory advanced colorectal cancer were randomized (1:1 ratio) to receive BBI608 (n = 138) vs. placebo (n = 144) after stratification by performance status, kirsten rat sarcoma viral oncogene homolog (KRAS) status, prior vascular endothelial growth factor inhibitor treatment, and time from diagnosis of metastatic disease.